SPECTRUM PHARMACEUTICALS, INC. ANNOUNCES A LICENSE AND COLLABORATION AGREEMENT FOR OZARELIX WITH NIPPON KAYAKU CO., LTD. FOR THE JAPANESE MARKET

Spectrum Pharmaceuticals, Inc. announced that its licensor for ozarelix, AEterna Zentaris, has entered into a licensing and collaboration agreement with Nippon Kayaku for the fourth generation luteinizing hormone-releasing hormone (LHRH) antagonist, ozarelix. Under the terms of the agreement, Nippon Kayaku has an exclusive license to develop and market ozarelix for all potential oncological indications in Japan.

BioSpace (http://www.biospace.com/news_story.aspx?StoryID=26442&full=1)